Fred Alger Management Inc. Has $452,000 Position in Five Prime Therapeutics, Inc. (FPRX)

Fred Alger Management Inc. increased its stake in shares of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) by 25.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,000 shares of the biotechnology company’s stock after acquiring an additional 3,000 shares during the period. Fred Alger Management Inc. owned about 0.05% of Five Prime Therapeutics worth $452,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of FPRX. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Five Prime Therapeutics during the first quarter worth about $593,000. American International Group Inc. grew its holdings in Five Prime Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 16,614 shares of the biotechnology company’s stock valued at $601,000 after purchasing an additional 1,100 shares during the period. Alliancebernstein L.P. grew its holdings in Five Prime Therapeutics by 9.2% in the first quarter. Alliancebernstein L.P. now owns 97,770 shares of the biotechnology company’s stock valued at $3,534,000 after purchasing an additional 8,220 shares during the period. AXA grew its holdings in Five Prime Therapeutics by 77.0% in the first quarter. AXA now owns 15,400 shares of the biotechnology company’s stock valued at $557,000 after purchasing an additional 6,700 shares during the period. Finally, FMR LLC grew its holdings in Five Prime Therapeutics by 1.8% in the first quarter. FMR LLC now owns 4,343,501 shares of the biotechnology company’s stock valued at $157,017,000 after purchasing an additional 77,381 shares during the period. 84.05% of the stock is currently owned by hedge funds and other institutional investors.

In related news, Director William R. Ringo sold 2,000 shares of the stock in a transaction on Thursday, September 28th. The stock was sold at an average price of $38.00, for a total value of $76,000.00. Following the transaction, the director now directly owns 2,000 shares of the company’s stock, valued at approximately $76,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director William R. Ringo sold 1,800 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $40.26, for a total value of $72,468.00. Following the completion of the transaction, the director now directly owns 1,200 shares in the company, valued at $48,312. The disclosure for this sale can be found here. Corporate insiders own 6.50% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://ledgergazette.com/2017/10/10/fred-alger-management-inc-has-452000-position-in-five-prime-therapeutics-inc-fprx.html.

Shares of Five Prime Therapeutics, Inc. (NASDAQ FPRX) opened at 38.02 on Tuesday. The firm’s market cap is $1.06 billion. Five Prime Therapeutics, Inc. has a 1-year low of $25.97 and a 1-year high of $60.98. The firm’s 50-day moving average price is $34.95 and its 200 day moving average price is $31.82.

Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($1.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.43). Five Prime Therapeutics had a negative return on equity of 31.78% and a negative net margin of 356.39%. The business had revenue of $7.80 million for the quarter, compared to analysts’ expectations of $8.32 million. During the same period in the prior year, the company earned ($0.49) EPS. The company’s revenue for the quarter was down 16.1% compared to the same quarter last year. On average, equities research analysts forecast that Five Prime Therapeutics, Inc. will post ($5.29) EPS for the current fiscal year.

Several analysts have commented on the company. Jefferies Group LLC reissued a “buy” rating and issued a $52.00 price objective (down from $55.00) on shares of Five Prime Therapeutics in a report on Thursday, August 10th. BidaskClub lowered Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 2nd. BMO Capital Markets reissued a “hold” rating and issued a $39.00 price objective on shares of Five Prime Therapeutics in a report on Friday, September 22nd. ValuEngine upgraded Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Finally, Royal Bank Of Canada began coverage on Five Prime Therapeutics in a research report on Thursday, September 14th. They issued an “outperform” rating and a $41.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. Five Prime Therapeutics has an average rating of “Buy” and a consensus price target of $57.50.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in

A number of other institutional investors also recently bought and sold shares of FPRX. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Five Prime Therapeutics during the first quarter worth about $593,000. American International Group Inc. grew its holdings in Five Prime Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 16,614 shares of the biotechnology company’s stock valued at $601,000 after purchasing an additional 1,100 shares during the period. Alliancebernstein L.P. grew its holdings in Five Prime Therapeutics by 9.2% in the first quarter. Alliancebernstein L.P. now owns 97,770 shares of the biotechnology company’s stock valued at $3,534,000 after purchasing an additional 8,220 shares during the period. AXA grew its holdings in Five Prime Therapeutics by 77.0% in the first quarter. AXA now owns 15,400 shares of the biotechnology company’s stock valued at $557,000 after purchasing an additional 6,700 shares during the period. Finally, FMR LLC grew its holdings in Five Prime Therapeutics by 1.8% in the first quarter. FMR LLC now owns 4,343,501 shares of the biotechnology company’s stock valued at $157,017,000 after purchasing an additional 77,381 shares during the period. 84.05% of the stock is currently owned by hedge funds and other institutional investors.

In related news, Director William R. Ringo sold 2,000 shares of the stock in a transaction on Thursday, September 28th. The stock was sold at an average price of $38.00, for a total value of $76,000.00. Following the transaction, the director now directly owns 2,000 shares of the company’s stock, valued at approximately $76,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director William R. Ringo sold 1,800 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $40.26, for a total value of $72,468.00. Following the completion of the transaction, the director now directly owns 1,200 shares in the company, valued at $48,312. The disclosure for this sale can be found here. Corporate insiders own 6.50% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://ledgergazette.com/2017/10/10/fred-alger-management-inc-has-452000-position-in-five-prime-therapeutics-inc-fprx.html.

Shares of Five Prime Therapeutics, Inc. (NASDAQ FPRX) opened at 38.02 on Tuesday. The firm’s market cap is $1.06 billion. Five Prime Therapeutics, Inc. has a 1-year low of $25.97 and a 1-year high of $60.98. The firm’s 50-day moving average price is $34.95 and its 200 day moving average price is $31.82.

Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($1.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.43). Five Prime Therapeutics had a negative return on equity of 31.78% and a negative net margin of 356.39%. The business had revenue of $7.80 million for the quarter, compared to analysts’ expectations of $8.32 million. During the same period in the prior year, the company earned ($0.49) EPS. The company’s revenue for the quarter was down 16.1% compared to the same quarter last year. On average, equities research analysts forecast that Five Prime Therapeutics, Inc. will post ($5.29) EPS for the current fiscal year.

Several analysts have commented on the company. Jefferies Group LLC reissued a “buy” rating and issued a $52.00 price objective (down from $55.00) on shares of Five Prime Therapeutics in a report on Thursday, August 10th. BidaskClub lowered Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 2nd. BMO Capital Markets reissued a “hold” rating and issued a $39.00 price objective on shares of Five Prime Therapeutics in a report on Friday, September 22nd. ValuEngine upgraded Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Finally, Royal Bank Of Canada began coverage on Five Prime Therapeutics in a research report on Thursday, September 14th. They issued an “outperform” rating and a $41.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. Five Prime Therapeutics has an average rating of “Buy” and a consensus price target of $57.50.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Want to see what other hedge funds are holding FPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Five Prime Therapeutics, Inc. (NASDAQ:FPRX).

Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply